Want to see IMUX full AI Analyst Report?
Immunic (IMUX) Stock Statistics & Valuation Metrics
Total Valuation
Immunic has a market cap or net worth of $102.47M. The enterprise value is $498.91M.
- Market Cap
- $102.47M
- Enterprise Value
- $498.91M
Share Statistics
Immunic has 13,644,467 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 13,644,467
- Owned by Insiders
- 12.38%
- Owned by Institutions
- 15.02%
Financial Efficiency
Immunic’s return on equity (ROE) is 14.56 and return on invested capital (ROIC) is 1693.37%.
- Return on Equity (ROE)
- 14.56
- Return on Assets (ROA)
- -4.04
- Return on Invested Capital (ROIC)
- 1693.37%
- Return on Capital Employed (ROCE)
- 15.72
- Revenue Per Employee
- 0
- Profits Per Employee
- -971.72K
- Employee Count
- 100
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Immunic is -1.56. Immunic’s PEG ratio is -0.02.
- PE Ratio
- -1.56
- PS Ratio
- 0.00
- PB Ratio
- 2.50
- Price to FCF
- -1.16
- Price to Operating Cash Flow
- -3.64
- PEG Ratio
- -0.02
Income Statement
In the last 12 months, Immunic had revenue of 0 and earned -97.17M in profits. Earnings per share was -6.24.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -103.23M
- Pretax Income
- -97.17M
- Net Income
- -97.17M
- EBITDA
- -97.00M
- Earnings Per Share (EPS)
- -6.24
Cash Flow
In the last 12 months, operating cash flow was -87.72M and capital expenditures -329,000, giving a free cash flow of -88.05M billion.
- Operating Cash Flow
- -87.72M
- Free Cash Flow
- -88.05M
- Free Cash Flow per Share
- -2.07
Dividends & Yields
Immunic pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -85.93%
- Earnings Yield
- -34.94%
Stock Price Statistics
- Beta
- 0.74
- 52-Week Price Change
- -4.23%
- 50-Day Moving Average
- 10.18
- 200-Day Moving Average
- 11.61
- Relative Strength Index (RSI)
- 40.27
- Average Volume (3m)
- 337.16K
Important Dates
Immunic upcoming earnings date is Feb 25, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Oct 29, 2026
- Next Earnings Date
- Feb 25, 2027
- Ex-Dividend Date
- ―
Financial Position
Immunic as a current ratio of 0.75, with Debt / Equity ratio of -10.25%
- Current Ratio
- 0.75
- Quick Ratio
- 0.75
- Debt to Market Cap
- 0.01
- Net Debt to EBITDA
- 0.15
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Immunic has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Immunic EV to EBITDA ratio is 0.47, with an EV/FCF ratio of 0.59.
- EV to Sales
- 0.00
- EV to EBITDA
- 0.47
- EV to Free Cash Flow
- 0.59
- EV to Operating Cash Flow
- 0.59
Balance Sheet
Immunic has $155.10M in cash and marketable securities with $567.00K in debt, giving a net cash position of $154.53M billion.
- Cash & Marketable Securities
- $155.10M
- Total Debt
- $567.00K
- Net Cash
- $154.53M
- Net Cash Per Share
- $11.33
- Tangible Book Value Per Share
- $3.00
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Immunic is $36.56, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $36.56
- Price Target Upside
- 386.76% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 11
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 50.66%
Scores
- Smart Score
- 6
- AI Score
- 43
